JAC Advance Access published online on December 1, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh495
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Laboratoire de Microbiologie, UFR des Sciences Pharmaceutiques et Biologiques, Université René Descartes, 75270 Paris Cedex 06, France
* To whom correspondence should be addressed. Objectives: The aim of our study was to analyse the antibiotic susceptibility of various strains of Bifidobacterium spp. to a wide range of antimicrobial agents. Methods: Fifty strains belonging to eight species of bifidobacteria, isolated from humans, animals or probiotic products, were tested for susceptibility to 30 antibiotics by disc diffusion on Brucella agar supplemented with 5% laked sheep blood and vitamin K1 (1 mg/L). MICs of nine anti-anaerobe agents, including three new molecules (telithromycin, linezolid and gatifloxacin), were determined using the reference agar-dilution method. Results: All strains of bifidobacteria, whatever the species, were sensitive to penicillins: penicillin G, amoxicillin (MIC50 0.06 mg/L), piperacillin, ticarcillin, imipenem and usually anti-Gram-positive antibiotics (macrolides, clindamycin, pristinamycin, vancomycin and teicoplanin). Susceptibility to cefalothin and cefotetan was variable. Most isolates (70%) were resistant to fusidic acid. As expected, high resistance rates were observed for aminoglycosides. Metronidazole, an agent known for its anti-anaerobe activity, was ineffective against 38% of the strains. The newly commercialized molecules, telithromycin, linezolid and gatifloxacin, were active with MIC50S of 1 mg/L. The only variation in susceptibility observed among the different species concerned Bifidobacterium breve, which appeared to be generally more resistant. Potentially acquired resistance was only observed against tetracycline and minocycline, in 14% of the strains. Conclusions: With regard to a general concern about the safety of probiotics, such as potential transferability of resistance determinants, bifidobacteria, with their low natural and acquired resistance to 30 antibiotics, appear risk-free.
Revised September 10, 2004
Accepted October 1, 2004
Original article
Antimicrobial susceptibility of bifidobacteria
2 INRA, Villeneuve d'Ascq, Virologie et Microbiologie Industrielle, UFR des Sciences Pharmaceutiques, Université Paul Sabatier, 31062 Toulouse cedex 4 France
3 EA3036 Laboratoire de Bactériologie, Virologie et Microbiologie Industrielle, UFR des Sciences Pharmaceutiques, Université Paul Sabatier, 31062 Toulouse cedex 4, France
4 Laboratoire de Microbiologie, UFR des Sciences Pharmaceutiques et Biologiques, Université René Descartes, 75270 Paris Cedex 06, France; Centre Hospitalier de Versailles, Le Chesnay, France
F. Doucet-Populaire, E-mail: florence.doucet-populaire{at}univ-paris5.fr
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in J. Antimicrob. Chemother.:
- Antimicrobial susceptibility of bifidobacteria
- C. Moubareck, F. Gavini, L. Vaugien, M. J. Butel, and F. Doucet-Populaire
J. Antimicrob. Chemother. 2005 10.1093/jac/dki162.[Abstract]
This article has been cited by other articles:
|
|
 |
|
  S. D. Mahlen and J. E. Clarridge III Site and Clinical Significance of Alloscardovia omnicolens and Bifidobacterium Species Isolated in the Clinical Laboratory J. Clin. Microbiol., October 1, 2009; 47(10): 3289 - 3293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Vasquez, A. Suau, F. Magne, P. Pochart, and M.-A. Pelissier Differential Effects of Bifidobacterium pseudolongum Strain Patronus and Metronidazole in the Rat Gut Appl. Envir. Microbiol., January 15, 2009; 75(2): 381 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Aires, F. Doucet-Populaire, and M. J. Butel Tetracycline Resistance Mediated by tet(W), tet(M), and tet(O) Genes of Bifidobacterium Isolates from Humans Appl. Envir. Microbiol., April 15, 2007; 73(8): 2751 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Moubareck, M. Lecso, E. Pinloche, M. J. Butel, and F. Doucet-Populaire Inhibitory Impact of Bifidobacteria on the Transfer of {beta}-Lactam Resistance among Enterobacteriaceae in the Gnotobiotic Mouse Digestive Tract Appl. Envir. Microbiol., February 1, 2007; 73(3): 855 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Margolles, A. B. Florez, J. A. Moreno, D. van Sinderen, and C. G. de los Reyes-Gavilan Two membrane proteins from Bifidobacterium breve UCC2003 constitute an ABC-type multidrug transporter Microbiology, December 1, 2006; 152(12): 3497 - 3505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Florez, M. S. Ammor, P. Alvarez-Martin, A. Margolles, and B. Mayo Molecular Analysis of tet(W) Gene-Mediated Tetracycline Resistance in Dominant Intestinal Bifidobacterium Species from Healthy Humans Appl. Envir. Microbiol., November 1, 2006; 72(11): 7377 - 7379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mohan, C. Koebnick, J. Schildt, S. Schmidt, M. Mueller, M. Possner, M. Radke, and M. Blaut Effects of Bifidobacterium lactis Bb12 Supplementation on Intestinal Microbiota of Preterm Infants: a Double-Blind, Placebo-Controlled, Randomized Study J. Clin. Microbiol., November 1, 2006; 44(11): 4025 - 4031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Masco, K. Van Hoorde, E. De Brandt, J. Swings, and G. Huys Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products J. Antimicrob. Chemother., July 1, 2006; 58(1): 85 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Margolles, J. A. Moreno, D. van Sinderen, and C. G. de los Reyes-Gavilan Macrolide Resistance Mediated by a Bifidobacterium breve Membrane Protein Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4379 - 4381. [Abstract] [Full Text] [PDF]
|
|